Novo Nordisk is expanding its use of Amazon Web Services (AWS) artificial intelligence tools across drug discovery. The pharmaceutical company will now use AI agents for target identification, therapy design, and research workflows — a move that brings what the industry calls "agentic AI" into the earliest stages of medicine development.
Under the agreement announced recently, AWS will become Novo Nordisk's preferred cloud provider and strategic AI partner. This is not just a cloud deal — it is a deeper collaboration aimed at changing how the company finds and designs new medicines.
New London co-innovation hub for AI drug discovery
The companies have also created a co-innovation hub at Novo Nordisk's existing London facility. This is where the real work will happen. According to StockTitan, the hub will bring Novo Nordisk R&D staff together with AWS engineers, AI specialists, applied scientists, and professional services teams.
The idea is simple: put the people who understand biology in the same room as the people who build AI tools. AWS said the arrangement is intended to reduce handoffs between computational analysis and laboratory research. In traditional drug discovery, data from lab experiments often moves slowly into computer models and back again. That back-and-forth wastes time. The new hub is designed to shorten that loop.
What agentic AI means for drug research
Agentic AI is different from standard AI tools. Instead of just answering questions or analyzing data when asked, agentic AI systems can take actions on their own — identifying targets, designing therapies, and managing research workflows without constant human input.
For Novo Nordisk, this means AI agents can work alongside scientists to speed up the early stages of drug development. The company is applying these tools across its research pipeline, according to PharmaPhorum.
The partnership builds on earlier work between the two companies. Novo Nordisk has already used AWS infrastructure for generative AI in drug discovery, as highlighted in an AWS video case study. The new agreement takes that relationship further, making AWS the backbone of Novo Nordisk's AI-driven research efforts.
Why this partnership matters for medicine development
Drug discovery is slow and expensive. It can take years and billions of dollars to bring a new medicine from an idea to a pharmacy shelf. A large part of that time is spent on early research — figuring out which biological targets matter, which molecules might work, and which approaches deserve deeper study.
AI agents can help with all of these steps. They can scan massive datasets, predict how molecules will behave, and suggest new approaches that human researchers might miss. By embedding these tools directly into Novo Nordisk's research workflow, the company hopes to make better decisions faster.
The London hub is central to this vision. It is not a remote consulting arrangement — it is a physical space where AWS and Novo Nordisk teams work side by side. That proximity matters. When AI engineers understand the real challenges of lab research, they can build better tools. When scientists understand what AI can do, they can ask better questions.
Our Take: AI agents are becoming core to pharma R&D
This partnership is a clear signal that agentic AI has moved from experimental to essential in the pharmaceutical industry. In our view, the most important part of this announcement is not the technology itself — it is the structure of the collaboration.
By placing AWS engineers directly inside a Novo Nordisk facility, the companies are acknowledging a simple truth: AI tools only work when they are built around real research problems. The old model of buying software and hoping it fits does not work for something as complex as drug discovery.
There are also practical implications for patients. Faster drug discovery does not guarantee faster cures, but it does mean that promising ideas can be tested sooner. For a company like Novo Nordisk — which works on diabetes, obesity, and other chronic conditions — that could translate into new treatment options reaching the market more quickly.
The real test will come in the results. Partnerships like this are easy to announce but hard to execute. The London hub gives this one a better chance than most, because it forces collaboration at the working level rather than just at the executive level. If the hub delivers on its promise, we can expect other pharmaceutical companies to follow the same playbook.
For now, the message is clear: agentic AI is no longer a future concept in drug discovery. It is being deployed today, in real labs, on real research problems.
